MedTrace Logo

PPMI Tau PET Imaging

NCT04906590 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-04-21

No results posted yet for this study

Summary

The Assessment of Brain Tau Burden in Participants with Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging) will evaluate if \[18F\] PI-2620 facilitates better understanding of Tau deposition in the brain in Parkinson's disease (PD).

Conditions

  • Parkinson Disease

Interventions

DRUG

[18F] PI-2620

Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.

Sponsors & Collaborators

  • Institute for Neurodegenerative Disorders

    collaborator OTHER

  • Michael J. Fox Foundation for Parkinson's Research

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-30
Primary Completion
2023-01-30
Completion
2023-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906590 on ClinicalTrials.gov